These results indicated that the survival of cells with acquired resistance to lorlatinib had a marginal dependency on EGFR signaling and that EGFR-targeted combination treatment might be more effective in the initial phase than at the lorlatinib-acquired resistance phase in ALK-rearranged NSCLC cells. The gene discussed is ALK; the disease is non-small cell lung carcinoma.